MERSANA THERAPEUTICS INC. - COMMON STOCK

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

08 Aug 2022 15:04:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2

08 Aug 2022 15:02:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Second Quarter 2022 Conference Call on August 8, 2022 and Present at Upcoming Conferences

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Chief People Officer Carla Poulson Named One of Savoy Magazine’s 2022 Most Influential Black Executives in Corporate America

22 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Jul 2022 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Upcoming Investor Conferences

26 May 2022 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to XMT-2056 for the Treatment of Gastric Cancer

19 May 2022 06:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results

09 May 2022 06:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 May 2022 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host First Quarter 2022 Conference Call on May 9, 2022

02 May 2022 07:00:02 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Apr 2022 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual Meeting

05 Apr 2022 07:00:02 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present an Analysis from the Expansion Cohort of the Phase 1 Trial of Upifitamab Rilsodotin at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer

15 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

02 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

28 Feb 2022 05:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2021 Financial Results and Business Updates

22 Feb 2022 07:00:02 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

10 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Research Collaboration and License Agreement with Janssen to Advance Novel Antibody-Drug Conjugates

03 Feb 2022 06:00:00 By Nasdaq GlobeNewswire